Received Feb 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | HA5HA | — |
Only adjuvant portion; Only adjuvant portion; late 2nd dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 51-year-old male patient who received Herpes zoster (Shingrix) (batch number HA5HA, expiry date 13-NOV-2026) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 17-MAY-2024). On 04-FEB-2025, the patient received the 2nd dose of Shingrix. On 04-FEB-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: Only adjuvant portion), inappropriate dose of vaccine administered (Verbatim: Only adjuvant portion) and drug dose administration interval too long (Verbatim: late 2nd dose ). The outcome of the inappropriate preparation of medication, inappropriate dose of vaccine administered and drug dose administration interval too long were unknown. Additional Information: GSK Receipt Date: 06-FEB-2025 The health care professional reported that he/she asked regards the Shingles vaccine (Shingrix), if a patient was given just the diluent only and not the vaccine it self, when was safe to get the dose of vaccine, which led to inappropriate preparation of medication and inappropriate doseof vaccine administered. The vaccine administration facility was the same as primary reporter. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule.